d -Mannose for Prevention of Recurrent Urinary Tract Infection Among Women
JAMA Internal Medicine · 01.06.2024 · 184 (6) · 619
DOI: 10.1001/jamainternmed.2024.0264 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Internal Medicine, erschienen am 01.06.2024. Verfasst von Gail Hayward und 15 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, England, United Kingdom. Hauptthemen laut MEDLINE: Mannose, Recurrence, Urinary Tract Infections. Die Arbeit wurde bisher 95-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Recurrent urinary tract infection (UTI) is a common debilitating condition in women, with limited prophylactic options. d -Mannose has shown promise in trials based in secondary care, but effectiveness in placebo-controlled studies and community settings has not been established.
Objective
To determine whether d -mannose taken for 6 months reduces the proportion of women with recurrent UTI experiencing a medically attended UTI. Design, Setting, and Participants This 2-group, double-blind randomized placebo-controlled trial took place across 99 primary care centers in the UK. Participants were recruited between March 28, 2019, and January 31, 2020, with 6 months of follow-up. Participants were female, 18 years or older, living in the community, and had evidence in their primary care record of consultations for at least 2 UTIs in the preceding 6 months or 3 UTIs in 12 months. Invitation to participate was made by their primary care center. A total of 7591 participants were approached, 830 responded, and 232 were ineligible or did not proceed to randomization. Statistical analysis was reported in December 2022.
Intervention
Two grams daily of d -mannose powder or matched volume of placebo powder. Main Outcomes and Measures The primary outcome measure was the proportion of women experiencing at least 1 further episode of clinically suspected UTI for which they contacted ambulatory care within 6 months of study entry. Secondary outcomes included symptom duration, antibiotic use, time to next medically attended UTI, number of suspected UTIs, and UTI-related hospital admissions.
Results
Of 598 women eligible (mean [range] age, 58 [18-93] years), 303 were randomized to d -mannose (50.7%) and 295 to placebo (49.3%). Primary outcome data were available for 583 participants (97.5%). The proportion contacting ambulatory care with a clinically suspected UTI was 150 of 294 (51.0%) in the d -mannose group and 161 of 289 (55.7%) in the placebo group (risk difference, −5%; 95% CI, −13% to 3%; P = .26). Estimates were similar in per protocol analyses, imputation analyses, and preplanned subgroups. There were no statistically significant differences in any secondary outcome measures. Conclusions and Relevance In this randomized clinical trial, daily d -mannose did not reduce the proportion of women with recurrent UTI in primary care who experienced a subsequent clinically suspected UTI. d -Mannose should not be recommended for prophylaxis in this patient group. Trial Registration isrctn.org Identifier: ISRCTN13283516
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, England, United Kingdom.
- Centre for Academic Primary Care, NIHR School for Primary Care Research, Bristol Medical School: Population Health Sciences, University of Bristol, Bristol, England, United Kingdom.
- Primary Care Research Centre, Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, England, United Kingdom.
- Windrush Medical Practice, Witney, England, United Kingdom.
- NIHR Clinical Research Network Thames Valley and South Midlands, Oxford, England, United Kingdom.
- Oxford Trauma and Emergency Care, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford University, England, United Kingdom.
Zitieren
APA
Hayward, G., Mort, S., Hay, A. D., Moore, M., Thomas, N. P. B., Cook, J., Robinson, J., Williams, N., Maeder, N., Edeson, R., Franssen, M., Grabey, J., Glogowska, M., Yang, Y., Allen, J., & Butler, C. C. (2024). d -Mannose for Prevention of Recurrent Urinary Tract Infection Among Women. JAMA Internal Medicine, 184(6), 619. https://doi.org/10.1001/jamainternmed.2024.0264
Vancouver
Hayward G, Mort S, Hay AD, Moore M, Thomas NPB, Cook J, et al. d -Mannose for Prevention of Recurrent Urinary Tract Infection Among Women. JAMA Internal Medicine. 2024;184(6):619. doi:10.1001/jamainternmed.2024.0264
BibTeX
@article{Hayward2024,
author = {Hayward, Gail and Mort, Sam and Hay, Alastair D and Moore, Michael and Thomas, Nicholas P B and Cook, Johanna and Robinson, Jared and Williams, Nicola and Maeder, Nicola and Edeson, Rebecca and Franssen, Marloes and Grabey, Jenna and Glogowska, Margaret and Yang, Yaling and Allen, Julie and Butler, Christopher C},
title = {d -Mannose for Prevention of Recurrent Urinary Tract Infection Among Women},
journal = {JAMA Internal Medicine},
year = {2024},
volume = {184},
number = {6},
pages = {619},
doi = {10.1001/jamainternmed.2024.0264}
}
EUVIMED